文献速递糖尿病肥胖与代谢综合征

降糖药物对糖尿病健康相关生活质量的影响:GRADE研究

Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
PubMed 文献 · Diabetes Care · 2024-01-01

GRADE研究纳入5047例二甲双胍单药治疗的近期诊断2型糖尿病患者,随机加用甘精胰岛素、格列美脲、利拉鲁肽或西格列汀。四种药物均未恶化健康相关生活质量;利拉鲁肽组第1年SF-36躯体成分评分较其他组改善,第2、3年不再显著。

要点

  • 四种降糖药物均未恶化健康相关生活质量。
  • 利拉鲁肽组第1年SF-36躯体成分评分改善,第2、3年无显著差异。
  • 利拉鲁肽组PCS改善约一半由第1年体重下降解释。

核心结论

  • 在2型糖尿病诊断10年内的患者中,二甲双胍加用利拉鲁肽第1年SF-36躯体成分评分较其他药物改善,第2、3年不再显著;改善与体重下降和基线BMI相关。

研究设计与样本

  • GRADE为随机对照试验,共5047例2型糖尿病病程<10年、糖化血红蛋白6.8-8.5%且二甲双胍单药治疗的患者,随机加用甘精胰岛素、格列美脲、利拉鲁肽或西格列汀。
  • 基线平均年龄57岁;基线时4885例完成HRQoL评估,第1、2、3年随访评估,采用QWB-SA和SF-36躯体(PCS)与心理(MCS)成分总结量表,意向性治疗分析。

主要发现

  • 四种药物均未恶化HRQoL;各时间点QWB-SA和MCS评分组间无差异。
  • 利拉鲁肽组第1年PCS评分较其他组改善,第2、3年不再显著。
  • 利拉鲁肽组第1年体重下降约解释其PCS评分较甘精胰岛素和格列美脲改善的一半。
  • 基线BMI上三分位的利拉鲁肽组第1年PCS评分改善最大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Diabetes is associated with reduced health-related quality of life (HRQoL). Information on the relationship between HRQoL and glucose-lowering medications in recently diagnosed type 2 diabetes (T2D) is limited. We assessed changes in HRQoL in participants with T2D receiving metformin plus one of four glucose-lowering medications in Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). RESEARCH DESIGN AND METHODS: A total of 5,047 participants, baseline mean age 57 years, with <10 years T2D duration and glycated hemoglobin level 6.8-8.5% and taking metformin monotherapy, were randomly assigned to glargine, glimepiride, liraglutide, or sitagliptin. HRQoL was evaluated at baseline for 4,885 participants, and at years 1, 2, and 3, with use of the self-administered version of the Quality of Well-being Scale (QWB-SA) and SF-36 physical (PCS) and mental (MCS) component summary scales. Linear models were used to analyze changes in HRQoL over time in intention-to-treat analyses. RESULTS: None of the medications worsened HRQoL. There were no differences in QWB-SA or MCS by treatment group at any time point. PCS scores improved with liraglutide versus other groups at year 1 only. Greater weight loss during year 1 explained half the improvement in PCS scores with liraglutide versus glargine and glimepiride. Liraglutide participants in the upper tertile of baseline BMI showed the greatest improvement in PCS scores at year 1. CONCLUSIONS: Adding liraglutide to metformin in participants within 10 years of T2D diagnosis showed improvement in the SF-36 PCS in comparisons with the other medications at 1 year, which was no longer significant at years 2 and 3. Improvement was related to weight loss and baseline BMI.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Cherrington AL, Tripputi MT, Younes N, et al. Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2024. PMID: 38190625. doi:10.2337/dc23-1648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。